Pulmonary fibrosis

This registry collects data on lung transplant patients whose donor lungs were preserved and transported using the LUNGguard or BAROguard devices. Researchers track outcomes such as primary graft dysfunction, rejection, survival, ICU and hospital stays, readmissions, and time on …

This Phase 2 trial tests an inhaled medication called mosliciguat in 135 people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The study measure…

This study looks at the long-term safety of an inhaled medication called treprostinil for people with fibrotic lung diseases like idiopathic pulmonary fibrosis. About 1,850 adults who completed a prior related study will take the drug and be monitored for side effects. The goal i…

This study tests an inhaled form of pirfenidone (AP01) in 375 adults with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. Participants receive either a high dose, low dose, or placebo twice daily for 52 weeks, alongside their usual care. T…

This Phase 2 trial tests whether anlotinib, a drug currently used for cancer, can help people with idiopathic pulmonary fibrosis (IPF) or progressive fibrosis-interstitial lung disease. The study involves 30 adults aged 40-85 and measures changes in lung function over 52 weeks. P…

This study is developing a new way to treat pulmonary fibrosis, a condition where the lungs become scarred and stiff. The approach uses tiny particles called liposomes, coated with hyaluronic acid, to deliver drugs directly to the cells that cause scarring. The research is being …

This study tests an experimental drug, BMS-986278, in about 1057 adults with progressive pulmonary fibrosis, a condition where lung scarring worsens over time. Participants receive either the drug or a placebo to see if it can slow lung function decline and is safe. The trial is …

This study tests an experimental drug called BMS-986278 in 1255 adults with idiopathic pulmonary fibrosis (IPF), a disease that causes progressive lung scarring. The goal is to see if the drug can slow the decline in lung function and is safe to take. Participants will receive ei…

This phase 2 trial tests an experimental drug called ENV-101 (taladegib) in 213 adults with idiopathic pulmonary fibrosis, a disease that causes lung scarring and makes breathing harder. Participants take either the drug or a placebo daily for several months. The main goal is to …

This early-stage study tests whether atezolizumab, a drug used for cancer, is safe for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. About 24 adults aged 50 and older with confirmed IPF will receive the drug. Research…

This early-stage study tests whether a person's own lung stem cells, grown from a small biopsy and given through an IV, are safe for treating idiopathic pulmonary fibrosis (IPF). Twenty-four adults with IPF will receive either a low or high dose of stem cells or standard care. Th…

This study tests whether the drug sirolimus can prevent lung scarring (fibrosis) in people hospitalized with severe COVID-19 pneumonia. About 60 adults who need extra oxygen will receive sirolimus to see if it reduces the chance of long-term lung damage. The goal is to find a way…

This phase 2 trial tests whether adding belumosudil (Rezurock) to standard care can prevent scarring in new kidney transplants. About 40 adults receiving their first or second kidney will be randomly assigned to get the drug or a placebo for a year. The study tracks serious side …

This phase 2 trial tests a new drug called LYT-100 (deupirfenidone) in 240 adults with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring and breathing difficulty. Participants receive either LYT-100, the existing drug pirfenidone, or a placebo. The main goa…

This early-stage trial tests whether an inhaled protein from donated fat tissue can help people with pulmonary fibrosis, a lung-scarring disease. Seven participants will inhale the protein every 3 days for 7 doses. The study measures safety and changes in breathing and quality of…

This study is testing a new tool that uses chest CT scans to help doctors more accurately diagnose different types of pulmonary fibrosis, a lung scarring disease. Researchers will first create the tool by analyzing scans from 300 patients, then test it on 100 additional patients.…

This study looks at whether training one leg at a time on a bike can help people with idiopathic pulmonary fibrosis (IPF) exercise longer. IPF makes it hard to breathe, so using fewer muscles may allow a better workout. The trial will compare one-legged cycling to the usual two-l…

This study follows 500 adults who had COVID-19 to see what health problems they face months later. Researchers will track symptoms like tiredness, breathing trouble, and lung damage. The goal is to learn how common these long-term issues are and who is most likely to have them.

This study collects and analyzes blood, DNA, and tissue samples from 315 adults with pulmonary fibrosis, their relatives, and healthy volunteers. The goal is to learn more about the disease's causes, not to test a new treatment. Researchers hope the findings will guide future the…

This study looks at lung tissue from 80 people with pulmonary fibrosis to find unique genetic markers linked to scarring. By analyzing gene activity, researchers hope to better understand the disease and pave the way for new diagnostic tools and treatments. Participants must be 1…

This study tests whether a radioactive tracer called 68Ga-FAPi-46 can light up areas of scarring (fibrosis) in the lungs of people with interstitial lung disease. Participants receive the tracer and undergo a PET/CT scan to see where it collects. The goal is to understand how the…

This study at Duke University tests whether a special MRI scan using inhaled xenon gas can detect changes in lung function over time in people with progressive pulmonary fibrosis. Sixty adults with various types of lung scarring will have MRI scans before starting anti-fibrotic m…

This study looks at how things in the environment and at work might affect people with interstitial lung diseases (a group of lung conditions). Researchers will ask 1,000 adults with a new diagnosis about their exposures to things like pollution, chemicals, and dust. The goal is …

This study follows 250 Italian adults with genetic forms of pulmonary fibrosis to see how their lung function changes over time. Researchers will track breathing tests and compare patients who receive immune-modulating drugs with those who do not. The goal is to understand how in…

This study follows 1,423 adults with idiopathic pulmonary fibrosis (IPF) for two years to learn how the disease progresses naturally. Researchers will track events like sudden worsening, hospital stays, and deaths. The goal is to better understand IPF patterns, not to test a new …

This study examines how well immunotherapy works for people with both lung cancer and pulmonary fibrosis (scarred lungs). Researchers will compare 200 patients with both conditions to similar patients without scarring, tracking survival and side effects. They also analyze tumor t…

This study looks at whether people with pulmonary fibrosis (a scarring lung disease) have shorter telomeres—the protective caps on the ends of chromosomes. Researchers will measure telomere length in blood samples from 100 Israeli patients and follow their health for two years. T…

This study follows 200 ICU patients with severe COVID-19 to see how often they develop lung scarring (pulmonary fibrosis). Researchers will use blood tests and CT scans to find early signs of scarring and identify risk factors. The goal is to understand how scarring affects recov…

This study explores whether a special MRI scan using xenon gas can spot early signs of lung scarring and heart strain in people with progressive lung fibrosis. About 30 adults already on anti-fibrotic medication will be scanned and followed over time. The goal is to see if this i…